Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. Kunz, P. L., Nandoskar, P., Koontz, M., Ji, H., Ford, J. M., Balise, R. R., Kamaya, A., Rubin, D., Fisher, G. A. AMER SOC CLINICAL ONCOLOGY. 2014
View details for DOI 10.1200/jco.2014.32.3_suppl.115
View details for Web of Science ID 000333682100120